Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 4;20(1):28.
doi: 10.1186/s12958-022-00892-8.

Therapeutic options for premature ovarian insufficiency: an updated review

Qiao-Yi Huang  1 , Shao-Rong Chen  1 , Jia-Ming Chen  1 , Qi-Yang Shi  2 , Shu Lin  3   4
Affiliations
Review

Therapeutic options for premature ovarian insufficiency: an updated review

Qiao-Yi Huang et al. Reprod Biol Endocrinol. .

Erratum in

Abstract

Primary ovarian insufficiency (POI) is a rare gynecological condition. This disease causes menstrual disturbances, infertility, and various health problems. Historically, hormone replacement therapy is the first-line treatment for this disorder. Women diagnosed with POI are left with limited therapeutic options. In order to remedy this situation, a new generation of therapeutic approaches, such as in vitro activation, mitochondrial activation technique, stem cell and exosomes therapy, biomaterials strategies, and platelet-rich plasma intra-ovarian infusion, is being developed. However, these emerging therapies are yet in the experimental stage and require precise design components to accelerate their conversion into clinical treatments. Thus, each medical practitioner bears responsibility for selecting suitable therapies for individual patients. In this article, we provide a timely analysis of the therapeutic strategies that are available for POI patients and discuss the prospects of POI therapy.

Keywords: In vitro activation; Mitochondrial activation technique; Platelet rich plasma; Premature ovarian insufficiency; Stem cell therapy; Therapeutic options.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interests.

Figures

Fig. 1
Fig. 1
Several treatments of premature ovarian failure. For POI patients, HRT is the first-line treatment. In vitro activation, mitochondrial activation technique, stem cell and exosomes therapy, biomaterials strategies, and platelet-rich plasma intra-ovarian infusion are a new generation of treatments for POI management
Fig. 2
Fig. 2
The PTEN/ PI3K / Akt / FOXO3 and Hippo signaling pathways regulates primordial follicles activation
Fig. 3
Fig. 3
Stem cell therapy mechanisms in primary ovarian insufficiency. During ovarian insufficiency, stem cells play multiple roles through homing, differentiation and paracrine stimulation. Paracrine signaling is the key for the improvement of damaged ovaries through anti-apoptosis, anti-fibrotic, angiogenesis, anti-inflammation, and immune regulation. In addition,stem cell-mediated exosomes and mitochondrial transfer demonstrate another novel mechanism
See this image and copyright information in PMC

References

    1. Beck-Peccoz P, Persani L. Premature ovarian failure. Orphanet J rare dis [internet]. Orphanet J Rare Dis. 2006; [cited 2020 Aug 8];1:9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16722528. - PMC - PubMed
    1. Nippita TA, Baber RJ. Premature ovarian failure: A review. Climacteric. Climacteric; 2007;10:11–22. - PubMed
    1. Lagergren K, Hammar M, Nedstrand E, Bladh M, Sydsjö G. The prevalence of primary ovarian insufficiency in Sweden; A national register study. BMC Womens Health. 2018;18:175. - PMC - PubMed
    1. Golezar S, Ramezani Tehrani F, Khazaei S, Ebadi A, Keshavarz Z. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019;22:403–411. doi: 10.1080/13697137.2019.1574738. - DOI - PubMed
    1. De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet. 2010;376:911–921. doi: 10.1016/S0140-6736(10)60355-8. - DOI - PubMed

MeSH terms